Person Centered Care Case Study

Figure 2. A descriptive observation of use of antipsychotic and Alternative therapies, a 2-year data at the Blue Care Aged care facility and the evidence that the evaluation of the antipsychotic program is effective in providing person centered care and helped in reducing the use of antipsychotic medication with alternative therapies, (APM) antipsychotic medication, (PCC) Person Centered Care.

Discussion with Board
Priorities for action: Information and communications technology solutions to be introduced into the residential aged care system in order to improve the effectiveness and efficiency of aged care
Benefits: The benefits include an improvement in documentation efficiency, less time for documentation, staffs to have better information
and knowledge of individual residents, whereby managing all records and information’s improving access to acquire funding. Convenience of distribution, storage, retrieval and efficiency in data entry, which will require less staffing.

Priorities for action: Regular medication reviews and educational programs, assessments has led to reduction in antipsychotic with less adverse events such as falls, pressure areas and skin tears was significantly less. Benefits: There would be a greater probability of the use of less specialist service utilisation, less nursing interventions which will enhance more time spent with residents, fewer incidents of undesirable behaviour, with less burden to the system.

Priorities for action: We should extend research in the clinical area, increase staff awareness of the limited effectiveness and possible adverse effects of antipsychotic medication and cost effectiveness of non-pharmacological methods such as music in treating behavioural problem in dementia.
Benefits: The consequences are that people will receive excellent care, it will also reduce staff distress and resolve management dilemmas, by recognizing the fundamental unsatisfiable need or cause, thus training and building talents are of paramount importance for upliftment of staff morale, staff retention, sustainability, and good practice. With a modest extra investment, the productive efficiency will help to maximize outcomes for a given cost.

Priorities for action: We can make these positive changes with modest increases in investment coupled with redesigning to the existing structure. Decisive local action should be considered using relevant data to generate goal and action planning. Change should take place ‘step by step’ and in small doses rather than change on a more radical scale. Impacts on staff will be mixed but generally improvements in
awareness
Benefits: Recommendation offers a constant fair and affordable way forward. Being able to see the benefits of change, either for residents or staff, is an important motivator for staff to either implement or maintain a change in practice. Improving the work environment, and improved learning experiences may result in gains that would have direct or indirect on cost effectiveness.

Priorities for action: Regular audits conducted for reduction in antipsychotic medication where benefit will out weigh risk and where we can be assured that patient are managed safely and effectively. Involve people with dementia, family and friends in decision-making. Regular mental health and GP meeting how to ensure that future use follows best practice.
Benefits: Preventing falls and minimising their harmful effects are critical for safety and quality of health care for all Australians, improved quality of nursing documentation will facilitate internal communication among the staff members, emphasizing the need for a partnership approach between the family of the person with dementia, the care staffs their treating doctor, pharmacist and all allied health professionals involved in this process will reduce the financial burden in the current health system.

Conclusion/Implications It is fortunate that so many effective treatments for depression exist, that these frequently complement one another, and that we can attempt to match treatments to patients’ needs and preferences. As the genetic basis of many psychiatric disorders becomes more clearly established it is likely that drugs specifically designed for particular sub-groups of receptors will be developed. The findings of all studies generally supported the hypotheses that there is no single drug or drug group that is consistently effective or superior to any other and that, as a consequence, multiple relatively broad range of drugs are used to treat BPSD,
Further research into the reasons for prescribing these agents should be conducted to understand the variation in prescribing patterns across the dementia specific care units around the world.
In addition facility factors such as staffing levels, nurses beliefs interdisciplinary communications and the availability of residents activities contribute to the prescribing culture. This could be helpful in trying to reduce antipsychotic drug use and stimulate the use of psychosocial alternative interventions. However, until new preventive or disease-altering medications are approved, physicians must optimize the use of available pharmaceutical and behavioral therapies. As more is learned about the combinatorial effects of these and other potential therapeutic options at all stages of dementia, the ability to significantly impact disease progression may one day be
realized.